FEATURED SEARCH TERM: hyperlipidemia
Adding extended-release niacin to simvastatin significantly reduced low density lipoprotein (LDL) levels among patients with type II hyperlipidemia, and did so more effectively than either medication alone, according to a small randomized study from the Atlanta VA Center and the Emory University School of Medicine. The results were most dramatic among subjects who had the highest LDL levels at baseline.
RESULT: Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type II Hyperlipidemia
Journal of the American College of Cardiology | Mar 27, 2012 (Abstract of conference poster)
Merck has published results of a study showing that for patients with many different types of hyperlipidemia, a combination of niacin with laropiprant (which reduces flushing caused by niacin) has consistent effects on lipoprotein particles. The combination is approved in the European Union but not yet in the United States.
RESULT: Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups
American Journal of Cardiovascular Drugs | 1 Jun 2012 (Free abstract. Full text $59.94)